Factors Affecting Disease-Free Survival in Operated Nonmetastatic Gastrointestinal Stromal Tumors

被引:5
作者
Sakin, Abdullah [1 ]
Can, Orcun [2 ]
Arici, Serdar [2 ]
Yasar, Nurgul [2 ]
Geredeli, Caglayan [2 ]
Demir, Cumhur [2 ]
Cihan, Sener [2 ]
机构
[1] Yuzuncu Yil Univ, Dept Med Oncol, Med Sch, Van, Turkey
[2] Univ Hlth Sci, Okmeydani Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey
关键词
Gastrointestinal stromal tumor; Disease-free survival; Imatinib; Overall survival; PROGNOSTIC-FACTORS; DIAGNOSIS; IMATINIB; GISTS; ERA; EPIDEMIOLOGY; EXPERIENCE; KIT;
D O I
10.1016/j.jss.2019.03.059
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Possibly originating from interstitial Cajal cells, gastrointestinal stromal tumors (GISTS) have variable biological behaviors. In this study, we aimed to examine the factors affecting the disease-free survival (DFS) in patients with GIST who underwent operation. Material and methods: The study included the patients who were followed up and treated for GIST in our oncology clinic between 2002 and 2017. The Armed Forces Institute of Pathology criteria (Miettinen risk score) were used for risk stratification of patients. Results: Seventy-four patients were included to the study, where female patients constituted 52.7%, and the median age was 56 (range: 24-83) y. Most common primary tumor location was the stomach (51.4%), followed by the small intestine (33.8%), colorectum (10.8%), and retroperitoneum (4.1%). Miettinen risk score showed 12 patients (16.7%) at very low risk, 15 patients (20.8%) at low risk, 18 patients (25%) at intermediate risk, and 27 patients (37.5%) at high risk. DFS was significantly lower in patients with small intestine involvement than in cases with stomach involvement (P = 0.004). DFS was significantly lower in patients at high risk than in patients with no high risk (P = 0.034). Small intestine localization (hazard ratio [HR], 8.98; 95% confidence interval [CI], 1.14-8.18), high-risk score (HR, 5.16; 95% CI, 1.42-12.75), c-kit positivity (HR, 0.24; 95% CI, 0.13-0.69), and adjuvant therapy (HR, 0.37; 95% CI, 0.20-0.92) were found to be the most significant factors affecting DFS. Conclusions: Our study showed negative effects of small intestine localization and high-risk category and positive effects of c-kit positivity and adjuvant therapy on DFS in patients with GIST who underwent operation. When a decision will be made in favor of adjuvant therapy, tumor localization and c-kit mutation should also be considered in addition to risk score. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:170 / 177
页数:8
相关论文
共 33 条
  • [1] Gastrointestinal stromal tumors (GISTs), 10-year experience: Patterns of failure and prognostic factors for survival of 127 patients
    Al-Kalaawy, M.
    El-Zohairy, Mohamed A.
    Mostafa, Ahmed
    Al-Kalaawy, A.
    El-Sebae, H.
    [J]. JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2012, 24 (01) : 31 - 39
  • [2] Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
    Balachandran, Vinod P.
    Cavnar, Michael J.
    Zeng, Shan
    Bamboat, Zubin M.
    Ocuin, Lee M.
    Obaid, Hebroon
    Sorenson, Eric C.
    Popow, Rachel
    Ariyan, Charlotte
    Rossi, Ferdinand
    Besmer, Peter
    Guo, Tianhua
    Antonescu, Cristina R.
    Taguchi, Takahiro
    Yuan, Jianda
    Wolchok, Jedd D.
    Allison, James P.
    DeMatteo, Ronald P.
    [J]. NATURE MEDICINE, 2011, 17 (09) : 1094 - U99
  • [3] Bertin M, 2007, HEPATO-GASTROENTEROL, V54, P124
  • [4] Gastrointestinal stromal tumors: A multicenter study of 1160 Turkish cases
    Bulbul Dogusoy, Gulen
    [J]. TURKISH JOURNAL OF GASTROENTEROLOGY, 2012, 23 (03) : 203 - 211
  • [5] Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry
    Call, Jerry
    Walentas, Christopher D.
    Eickhoff, Jens C.
    Scherzer, Norman
    [J]. BMC CANCER, 2012, 12
  • [6] A prospective epidemiological study of new incident GISTs during two consecutive years in Rhone Alpes region: incidence and molecular distribution of GIST in a European region
    Cassier, P. A.
    Ducimetiere, F.
    Lurkin, A.
    Ranchere-Vince, D.
    Scoazec, J-Y
    Bringuier, P-P
    Decouvelaere, A-V
    Meeus, P.
    Cellier, D.
    Blay, J-Y
    Ray-Coquard, I.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 103 (02) : 165 - 170
  • [7] The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998-2008: a nation-wide cancer registry-based study
    Chiang, Nai-Jung
    Chen, Li-Tzong
    Tsai, Chia-Rung
    Chang, Jeffrey S.
    [J]. BMC CANCER, 2014, 14
  • [8] El Rassy Elie, 2017, Gulf J Oncolog, V1, P38
  • [9] Clinicopathological features and prognosis of colonic gastrointestinal stromal tumors: evaluation of a pooled case series
    Feng, Fan
    Tian, Yangzi
    Liu, Zhen
    Xu, Guanghui
    Liu, Shushang
    Guo, Man
    Lian, Xiao
    Fan, Daiming
    Zhang, Hongwei
    [J]. ONCOTARGET, 2016, 7 (26) : 40735 - 40745
  • [10] Diagnosis of gastrointestinal stromal tumors: A consensus approach
    Fletcher, CDM
    Berman, JJ
    Corless, C
    Gorstein, F
    Lasota, J
    Longley, BJ
    Miettinen, M
    O'Leary, TJ
    Remotti, H
    Rubin, BP
    Shmookler, B
    Sobin, LH
    Weiss, SW
    [J]. HUMAN PATHOLOGY, 2002, 33 (05) : 459 - 465